Invention Grant
- Patent Title: Pyrrolo[2,3-D]pyrimidinyl, pyrrolo[2,3-B]pyrazinyl, pyrrolo[2,3-B]pyridinyl acrylamides and epoxides thereof
-
Application No.: US15569874Application Date: 2016-04-19
-
Publication No.: US10703756B2Publication Date: 2020-07-07
- Inventor: Atli Thorarensen , Matthew Frank Brown , Agustin Casimiro-Garcia , Ye Che , Mark Edward Flanagan , Adam Matthew Gilbert , Matthew Merrill Hayward , Jean-Baptiste Telliez , Rayomand Jal Unwalla , John I. Trujillo , Sidney Xi Liang
- Applicant: Pfizer Inc.
- Applicant Address: US NY New York
- Assignee: Pfizer Inc.
- Current Assignee: Pfizer Inc.
- Current Assignee Address: US NY New York
- Agent A. David Joran
- International Application: PCT/IB2016/052220 WO 20160419
- International Announcement: WO2016/178110 WO 20161110
- Main IPC: C07D487/04
- IPC: C07D487/04
![Pyrrolo[2,3-D]pyrimidinyl, pyrrolo[2,3-B]pyrazinyl, pyrrolo[2,3-B]pyridinyl acrylamides and epoxides thereof](/abs-image/US/2020/07/07/US10703756B2/abs.jpg.150x150.jpg)
Abstract:
The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, and pyrrolo[2,3-b]pyridinyl acrylamides, epoxides, and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.
Public/Granted literature
Information query